ReviewJournal of the American Heart Association2020
Guidance on Short-Term Management of Atrial Fibrillation in Coronavirus Disease 2019.
Review in Journal of the American Heart Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 43 citations in OpenAlex.
- Emergence of Atrial Fibrillation and Flutter in COVID-19 Patients: A Retrospective Cohort Study.Healthcare (Basel, Switzerland) · 2024Article
- Trends in Atrial Fibrillation and Ablation Therapy During the Coronavirus Disease 2019 Pandemic.The Journal of innovations in cardiac rhythm management · 2024Article
- Influence of the COVID-19 pandemic on patients receiving oral anticoagulants for the treatment of non-valvular atrial fibrillation.International journal of cardiology. Heart & vasculature · 2024Article
- New-onset atrial fibrillation among COVID-19 patients: A narrative review.World journal of critical care medicine · 2023Review
- COVID-19 pandemic and initiation of treatment for atrial fibrillation: a nationwide analysis of claims data.BMC cardiovascular disorders · 2023Article
- A Delphi consensus on the management of anticoagulation in the COVID-19 pandemic: the MONACO study.Cardiovascular diagnosis and therapy · 2023Review
- COVID-19 HEART unveiling as atrial fibrillation: pathophysiology, management and future directions for research.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2023Review
- Bioinformatics-based investigation on the genetic influence between SARS-CoV-2 infections and idiopathic pulmonary fibrosis (IPF) diseases, and drug repurposing.Scientific reports · 2023Article
- Acute COVID-19 Management in Heart Failure Patients: A Specific Setting Requiring Detailed Inpatient and Outpatient Hospital Care.Biomedicines · 2023Review
- Safety of Adenosine for the Treatment of Supraventricular Tachycardia in Hospitalized Patients with COVID-19 Pneumonia.Journal of clinical medicine · 2023Article
- Identification of host genomic biomarkers from multiple transcriptomics datasets for diagnosis and therapies of SARS-CoV-2 infections.PloS one · 2023Article
- Physiologically-Based Pharmacokinetic Modeling-Guided Dose Management of Oral Anticoagulants when Initiating Nirmatrelvir/Ritonavir (Paxlovid) for COVID-19 Treatment.Clinical pharmacology and therapeutics · 2022Article
- Prevalence of bleeding secondary to anticoagulation and mortality in patients with atrial fibrillation admitted with SARS-CoV-2 infection.Medicina clinica · 2022Article
- Prevalence of bleeding secondary to anticoagulation and mortality in patients with atrial fibrillation admitted with SARS-CoV-2 infection.Medicina clinica (English ed.) · 2022Article
- Incidence, Mortality, and Imaging Outcomes of Atrial Arrhythmias in COVID-19.The American journal of cardiology · 2022Article
- Medium-Term Outcomes in COVID-19.Journal of clinical medicine · 2022Article
- Incidence of Atrioventricular Blocks and its Association with In-Hospital Mortality and Morbidity in Patients with Coronavirus Disease 2019.Journal of cardiology · 2022Article
- Pharmacotherapeutic agents for the management of COVID-19 patients with preexisting cardiovascular disease.Expert opinion on pharmacotherapy · 2021Review
- Atrial fibrillation and the risk of 30-day incident thromboembolic events, and mortality in adults ≥ 50 years with COVID-19.Journal of arrhythmia · 2021Article
- Editorial to "Atrial fibrillation and the risk of 30-day incident thromboembolic events and mortality in adults ≥50 years with COVID-19".Journal of arrhythmia · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation is a common clinical manifestation in hospitalized patients with coronavirus disease 2019 (COVID-19). Medications used to treat atrial fibrillation, such as antiarrhythmic drugs and anticoagulants, may have significant drug interactions with emerging COVID-19 treatments. Common unintended nontherapeutic target effects of COVID-19 treatment include potassium channel blockade, cytochrome P 450 isoenzyme inhibition or activation, and P-glycoprotein inhibition. Drug-drug interactions with antiarrhythmic drugs and anticoagulants in these patients may lead to significant bradycardia, ventricular arrhythmias, or severe bleeding. It is important for clinicians to be aware of these interactions, drug metabolism changes, and clinical consequences when choosing antiarrhythmic drugs and anticoagulants for COVID-19 patients with atrial fibrillation. The objective of this review is to provide a practical guide for clinicians who are managing COVID-19 patients with concomitant atrial fibrillation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.